Mantle cell lymphoma is characterized by a genetic defect that results in increased production of a protein called Cyclin D1. Another protein called Cdk4/6 works together with Cyclin D1 to release a brake on cell replication. For that reason, mantle cell lymphoma cells replicate more rapidly than other cells.
PD 0332991 is an investigational oral drug (i.e., a pill) that specifically inhibits Cdk4/6. Data from our lab and from an earlier clinical trial performed at Weill Cornell Medical Center suggest that PD 0332991 is able to stop lymphoma cells from replicating in some patients with mantle cell lymphoma.
Bortezomib (Velcade) is approved by the FDA for treatment of patients with relapsed mantle cell lymphoma. Data from our laboratory suggests that PD 0332991 and bortezomib can work together to kill lymphoma cells more effectively than either drug alone.
In this study, we are testing different doses of the combination of PD 0332991 and bortezomib. We hope to learn how to safely combine the two drugs. We also hope to learn more about how both drugs work so that we can use them more effectively in the future.
To learn more about this study, please contact June Greenberg, RN at (212) 746-2651 or email June at jdg2002@med.cornell.edu.
Click here to view the clinical and research profile of Dr. Peter Martin, the physician leading the study. Click here to view all non-Hodgkin clinical trials at Weill Cornell Medical Center.
New Developments in Lymphoma 